In this review recent progress in the development of heat shock proteins (Hsp90) in oncogenesis is illuminated. Particular emphasis is put on inhibitors such as geldanamycin and analogues that serve as a natural product show case. Hsp90 has emerged as an important target in cancer therapy and/or against pathogenic cells which elicit abnormal Hsp patterns. Competition for ATP by geldanamycin and related compounds abrogate the chaperone function of Hsp90. In this context, this account pursues three topics in detail: a) Hsp90 and its biochemistry, b) Hsp90 and its role in oncogenesis and c) strategies to create compound libraries of structurally complex inhibitors like geldanamycin on which SAR studies and the development of drugs that are currently in different stages of clinical testing rely.
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Introduction
Cancer is still a leading cause of death worldwide with a mortality rate of around 13% in 2008 and general therapies are far from being a reality yet.
1 It has been shown that cancer can originate from an excessive function of proteins or chaperone associated protein misfolding.
2 Misfolded proteins may trigger loss of normal functions and lead to deregulated physiological functions in cells. The function of molecular chaperones is to maintain the proper folding of proteins, which is important in cellular homeostasis to keep the balance between protein synthesis and degradation. Heat shock proteins (Hsps) belong to a family of molecular chaperones of which Hsp90, a highly conserved 90 kDa protein, is the most abundant eukaryotic heat shock protein, but it is also found in bacteria (HtpG).
3 Generally, binding of natural ligands, such as adenine nucleotides (ATP/ADP), co-chaperones, and client proteins can alter the conformation of Hsp90. 4 A series of small molecules, in particular natural products, have been identied to compete for different binding sites of natural Hsp90, thus inhibiting its chaperone function. The most famous example is probably the ansamycin antibiotic geldanamycin 1 as well as related secondary metabolites like herbimycin 2 and macbecin 3 (both quinone and hydroquinone forms exist) and the phenolic metabolite reblastatin (5) (Fig. 1) .
5 Also autolytimycin (4) was isolated in the early 2000s, both from Streptomyces sp. S6699 as well as from a culture broth of Streptomyces autolyticus JX-47 from which its name was derived. 6a Only recently, Wu and coworkers reported several new metabolites 6-8 from Streptomyces hygroscopicus 17997, all of which are functionalised at C-19.
6c-e
It is important to note that these natural products have paved the way for a deeper understanding of heat shock proteins, and as a result Hsp90 has emerged as a remarkable therapeutic target for the treatment of cancer. In this context the identication of binding sites of the target receptor, such as Hsp90, that signicantly affect its function is important. This review is intended to provide an overview and a story on rstly the biochemistry of heat shock protein 90 which will be linked to biomedical and pharmaceutical aspects and options for cancer therapy. Secondly, the preparation of geldanamycin libraries to uncover structure-activity relationship (SAR) knowledge will be discussed in detail as geldanamycin is a showcase for generating libraries by chemical as well as biosynthetic methods.
Thirdly, issues on assaying the inhibition of Hsp90 by geldanamycin (1) will be included in the review, that along with synthetic efforts resulted in "SAR-mapping" of this complex natural product.
2 Biological aspects of Hsp90 as target in cancer therapy
General and structural aspects of Hsp90
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form is a homodimer. Primarily, the heat shock proteins are classied and named by their molecular weight, a newer nomenclature annotates them as HSPC members (with ve known genes in the human genome) with HSPC1 for Hsp90, HSPC2 for Hsp90a and HSPC3 for HSPb. 10 Each monomer consists of four structural domains, the C-terminal (CTD) and N-terminal (NTD) and a middle domain (MD) connected to the NTD through an unstructured linker region.
11 Hsp90 exists in four different isoforms present in eukaryotic cells and plays a central role in the complex network of cellular functions. 12 The heat shock protein Hsp90 is part of a huge interactome, formed by co-chaperones, chaperones and clients.
13
Hsp90 plays a central role and interacts with many other human proteins. Computational approaches such as STRING (search tool for recurring instances of neighbouring genes) were developed to visualise relevant interactome routes, which can also be applied to Hsp90 (Fig. 2) . STRING is able to lter data from more than 1000 organisms, 5 million proteins and >200 million interactions stored.
13a,b Hits are ranked (0 is no and 1 the highest interaction) and the relationship between two genes is presented by lines, whereas strong interactions are monitored by an increase of line intensities. In Fig. 2 , candidates (colored balls) interacting with human Hsp90 (dark red ball) are ordered with respect to 10, 50 and 500 candidates. Eleven high scoring candidates (0.999-0.997) are CDC37, NR3C1, HIF1A, RAF1,  STIP1, AHSA1, NOS3, AKT1, PTG/ES3, ESR1, FKBP5 , all of which are well-known targets in cancer diagnostics and therapy. This tool nds support by LUMIER (luminescence-based mammalian interactome mapping) an automated HTP technology for the systematic mapping of protein-protein-interaction networks in mammalian cells.
14 These maps unravel the central physiological role of Hsp90 and direct and indirect contact partners can be identied as part of a huge interactome network that adds up to 600 partners. Clearly, this huge network also demonstrates that all the biological roles and diverse functions of Hsp90 are not yet fully understood and the discussion to follow can only provide a current and incomplete view on Hsp90.
As mentioned above, ve human Hsp90 family members are known: a) HSP90AA1 (HSPC1), b) Hsp90a (HSPC2), c) Hsp90b (HSPC3), d) the glucose-regulated protein 94 (Grp94) (HSPC4), and e) the tumor necrosis factor receptor-associated protein 1 (Trap-1, HSPC5). All members work in a similar fashion, but they do interact with different client proteins. Hsp90a and Hsp90b are closely related cytoplasmic isoforms. 15 The expression of Hsp90a is associated with proliferation of cancer cells and tumor progression, whereas the Hsp90b isoform is related to drug resistance. 16 The Hsp90 monomer, which in fact is commonly homodimerised, has three functional domains (Fig. 3) : a) an N-terminal nucleotide binding domain (NBD, 25 kDa) which accommodates ATP as well as some Hsp90 inhibitors like geldanamycin (1), b) the middle domain (MD, 55 kDa) where the docking sites for co-chaperones and client proteins are located and c) the C-terminal domain (CTD, 10 kDa) with the C-terminal dimerisation domain (CDD). The latter is also able to interact with ATP, co-chaperones and few Hsp90 inhibitors, such as novobiocin (9).
17 The charged domain between the NBD and CDD serves as a linker region and chaperone activity is established by dimerisation at the CDD domain. Co-chaperones and post-translational modications of Hsp90 modulate its chaperone activity. By inhibiting the Hsp90 chaperone, interference in cancer cell cycles becomes possible. Thus, compounds that are able to bind to different sites in Hsp90 are potential anticancer drugs. Today three major strategies for inhibiting Hsp90 function are being pursued. These are: a) the inhibition of ATPase activity by binding at the N-terminal nucleotide binding pocket for which geldanamycin (1), radicicol (13) and PU-H71 (12) are excellent examples (Fig. 7) , b) altering the conformation of Hsp90 activity with small molecules like novobiocin (9) (Fig. 4) that bind to the C-terminal dimerisation domain (CDD) and c) the inhibition of co-chaperones-binding, such as Cdc37 which is overexpressed in cancer cells, with Hsp90, as imposed by gedunin (10) and celastrol (11) (Fig. 4) .
In addition, Hsp90 activity is regulated by targeting sites relevant for the association of Hsp90 with client proteins, sites that modulate Hsp90 activity as well as sites for the inhibition of post-translational modications, such as phosphorylation, acetylation and S-nitrosylation. Details on the biological background of these options are discussed in the following chapters.
Functional aspects of Hsp90
2.2.1 Role in carcinogenesis. Heat shock proteins (Hsp's) are essential for the survival of organisms. In contrast to what the name may suggest, heat shock proteins are not only induced by heat but also by cellular stress situations, such as exposure to UV radiation, nutrient deprivation or oxygen deciency
19,20
Hsp's and especially human heat shock protein 90 (Hsp90) strongly interfere with diverse cellular processes, which include heat shock and other stress responses, signal transduction to chromatin-remodeling, telomerase maintenance and others. Hsp90 is also located in the nucleus where it interacts with chromatin-remodeling complexes.
21,22a A link to the histone methyltransferase SMYD3 was also found.
22b Additionally, Hsp co-chaperones inuence DNA helicases in yeast.
20f Examinations in yeast revealed that Hsp82p, the yeast homologue of Hsp90, is required for both DNA binding and extension of the telomerase.
23 The non-chaperone activity might provide a point of intervention to mitigate excessive telomerase function and may be a noteworthy aspect of cancer etiology. Shortening of telomeres by telomerase activity is correlated with age. For the development of anti-aging concepts, interference in the folding of telomerase by Hsp90 inhibitors may be a feasible strategy. In the context of therapeutic exploitation of Hsp90 inhibition, it is important to understand the effect and relevance of high or low Hsp90 activity for the cell. Along this line it will be important to establish a correlation between drug-induced levels of Hsp90 and associated toxic side effects.
Besides the role in the nucleosome, Hsp90 client management affects various other cellular processes. Hsp90 governs the folding process of nascent polypeptides leading to maturation and formation of intact and functional three-dimensional structures.
24 Not only de novo synthesised proteins are folded by Hsp90, but also proteins that have been denatured by cellular stress. The cellular response to stress is highly conserved in prokaryotes and all species of eukaryotes. It represents a general mechanism for the maintenance of cellular processes. In addition, it is a protection mechanism against the formation of protein aggregates in cytosol, whereas in some prokaryotes Hsp90 is dispensable under heat stress. 25 The initiation of Hsp90 synthesis and other Hsp's are evoked by specic transcription factors, so-called heat shock factors (HSF's). The trimeric form of HSF shows a high affinity for cis-acting DNA sequence elements (heat shock elements; HSEs) in the promoter region of heat shock protein genes. 26 The bound trimer forms a complex that activates transcription of the Hsp90 gene. Hsp90 is in direct contact with HSF, and stress can signicantly increase Hsp90 expression.
5a,27 The unique property of Hsp90 to fold nascent as well as denatured proteins, including mutant forms of proteins, has a special impact for cancer and therefore represents an ideal target for drug development.
20a,28
Due to the antiapoptotic nature of Hsp90, cells can survive stress with the side effect that this property also helps cancer cells in survival. The increased expression of Hsp90 under conditions of stress is a rescue mechanism of cells, because the proteins are protected from degradation by the proteasomic system. Furthermore, the "recycling" of proteins by Hsp90 clearly has advantages in terms of energy balance compared to de novo protein synthesis. For several proteins, which are also known as client proteins or target proteins, Hsp90 is required for preserving their stability and activity. Client proteins comprise up to 600 proteins, including proteins with exceptional features in signal transduction, cell growth and division. For example, receptors such as connexin, 29 steroid hormones, transcription factors and tumor suppressor proteins are Hsp90 dependent.
22d
If protein aggregates are not eliminated by the proteasome, apoptosis is initiated.
20f,30 Thus, this process is a key element in cancer therapy, when Hsp90 function can be suppressed by inhibitors. Besides its importance in cancer therapy, Hsp90 along with its homologues (HtpG's in prokaryotes), has emerged to be an attractive target combating other diseases, since there are homologous representatives in nearly all prokaryotic and eukaryotic cells.
31 Indeed, a link to other diseases, like neurological disorders, malaria or leishmania, is known. The development of different virus proteins are also Hsp dependent. 32 Yet another implication of Hsp90 (and Grp94) is in processing antigens and helping to deliver them to the cell surface in MHC complexes or higher Hsp70 levels in human T-cells. 33 This strategy, however, can lead to a problematic situation for adherent therapies, since immune defense could be differently affected by high or low Hsp activity. Under non stress conditions 1-2% Hsp90a and Hsp90b are present in the cell as cytosolic proteins. Hsp90a serves as the inducible and Hsp90b as the constitutive form. GRP94 is found in the endoplasmic reticulum and TRAP-1 is localised in the mitochondrial matrix. Except for Hsp90N, which has no NTD, all forms of Hsp90, including the bacterial homologue HtpG, are able to hydrolyse ATP. Unlike the other isoforms of Hsp90, the cytosolic function of Hsp90 is highly dependent on a number of co-chaperones, as is described in the next chapter.
2.2.2 The ATP and conformational cycle. The dimeric form of Hsp90 (I/II) acts as a molecular "clip" and suffers from conformational change by an ATP-dependent folding cycle (Fig. 5) . 20a,32,34 During the ATPase cycle, Hsp90 undergoes dimerisation at the N-terminus (II). Association of ATP (III) at this domain is the driving force for this step. The target client proteins are captured with the open form (V-shape) of Hsp90.
21, 35 As a result binding of ATP promotes closure of the lid of the N-terminal ATP-binding pocket, the coming together of the two N-termini of Hsp90 and a conformational change from the closed into the twisted form while "trapping" the client. Aer hydrolysis of ATP, Hsp90 folds back into its original shape and the open molecular "clip" is regenerated. Binding and subsequent release of the client proteins with the participation of co-chaperones is a dynamic process, whereas the rate of ATP hydrolysis and the conformational change between the different Hsp-conformers varies. For the human Hsp90, this is a slow turnover rate of 3 ATP h À1 . 36 The conformational change does not necessarily depend on ATP; so the closed form of Hsp90 is also found in the absence of ATP. It is rather assumed that ATP merely shis the balance between the "open" and "closed" form of Hsp90. Recent data obtained from single molecule measurements showed that ATP can bind at the Nterminus of the open and closed states (III to IV) without strictly forcing the protein into a specic conformation. The switches between the conformational and binding states are mainly thermally driven. Interestingly, ATP binds with different rates to the two monomeric units (negative cooperativity).
37 These studies also revealed that the C-terminus shows a dynamic behavior. The C-terminus (IV) opens and closes with fast kinetics, having a modulating effect on the binding of nucleotides to the N-terminal domain.
38
Although Hsp's and HtpG share a high degree of homology, drastic differences in structure and function between Hsp's and HtpG's are found in crystal structures, the interactome and ATP hydrolysis rates.
39
The regulation of the ATPase activity and selectivity for client proteins by cytosolic Hsp90 are signicantly inuenced by cochaperones. In fact, more than 20 co-chaperones regulate Hsp90 by modulating ATP hydrolysis (V/VI) (Aha1, Cdc37, p23), by inuencing the conformational exibility (p23, Sgt1) and by regulating complex assembly (Hop, Cdc37, Sgt1). They may also be required for folding other co-chaperones, such as Hsp70 and Hsp40. 40 During the ATPase cycle in eukaryotes different cochaperones assemble to yield the so-called "multi-chaperone" machinery. 41 The whole process was examined in detail for the maturation of a steroid hormone receptor in yeast. The cycle starts with association of the newly synthesised and still unfolded protein to an early complex of heat shock proteins Hsp70/Hsp40 (I) (Fig. 6) . forward and backward reaction rates are different for the individual Hsp90 proteins and may be subjected to regulation by co-chaperones, such as Aha1, Hop, Cdc37 and p23 (see Fig. 6 ). 43 It has been proposed, that Aha1 competes for p23. Accompanied by ATP hydrolysis, the correctly folded protein is released from the multi-chaperone complex, furnishing complex (VI) directly. Several other co-chaperone proteins like Cdc37 act as adapters by recruiting a specic range of client proteins (kinases). They bind to the open form of Hsp90, so that the dimerisation of the N-terminal domain is prevented and the ATPase cycle is interrupted.
Having outlined the basic features of the ATPase cycle, the focus will next be directed both towards regulation as well as integration of client interaction. At the beginning of the cycle, the N-terminal dimerisation can be thwarted by Hop (Sti1) or Cdc37.
44 Hop has two TPR domains that bind a conserved domain at the C-terminus of Hsp90 (sequence MEEVD) and Hsp70, respectively. 39, 45 It should be noted, that both Hsp70 and Hsp40 induce binding of steroid hormone receptors to Hsp90 during the process of receptor activation. 45 Meanwhile, Cdc37 constitutes a co-chaperone that plays a key role as an adapter for the kinase fold, selectively enabling strong or weak client interactions.
14, 46 These observations unravel the heterogeneity of the co-chaperones for different client classes and provokes the need to identify 'general' co-chaperones, i.e. those that participate at least in the majority of folding processes. This approach should provide domain-specic Hsp90 inhibitors that do not bind to the NTD or CTD. It is known that p23 and Sgt1 stabilise the closed ATP-bound state and slow down ATP hydrolysis.
44a Therefore, these and other co-chaperones play a fundamental role beyond regulating the cycle. For instance, in selected cases these co-chaperones have been linked to quality control of the client proteins, as shown for the mutant cystic brosis transmembrane conductance regulator (CFTR). 48 Still, signicant knowledge gaps have to be acknowledged. There are likely many more co-chaperones than those described here. A rst step towards a rational drug design would be to understand how many co-chaperones involved in a given folding cycle need to be addressed by a drug to achieve best inhibition. It has to be determined, if initial bonding contacts are mediated by cochaperones or by the client itself. If possible, targeting cochaperone interaction seems to be more sensible, given the much greater variety of existing clients compared to co-chaperones. For solitary clients a surface motif that mediates binding to an Hsp90-Cdc37 complex has been analysed for kinase clients. 47 Here, the aC-b4 loop region of various members of the kinase families is sufficiently conserved and represents a common recognition motif. Apart from that, there is little information available so far on other client classes or specic client-binding sites at Hsp90.
2.2.3 Post-translational regulation of Hsp90. Post-translational modications, that include phosphorylation, acetylation, nitrosylation and methylation, are supposed to be ne tuning mechanisms of the cell for adjusting Hsp90 activity.
49
When the charged linker region of Hsp90 is phosphorylated, client maturation of the aryl hydrocarbon receptor (AHR) is hindered. 50 This receptor is a cytosolic transcription factor. It is attached to several co-chaperones binding several exogenous ligands, such as natural plant avonoids, polyphenolics and indoles, as well as synthetic polycyclic aromatic hydrocarbons and dioxin-derived compounds. In addition, many kinases that regulate Hsp90 phosphorylation are Hsp90 clients themselves.
51
Acetylation can inuence client protein maturation and co-chaperone binding, and it is reported that acylation may reduce ATP binding of Hsp90.
52
S-nitrosylation at the C-terminal domain of Hsp90 leads to the reduction of Hsp90 ATPase activity.
53 SMYD3, a lysine methyltransferase, is upregulated in several cancer cells, and it was found that its catalytic activity is enhanced by the interaction with Hsp90. 54 2.2.4 Client processing. One prevalent property of Hsp90 is its contribution to client protein folding, maturation and activation. Although it is generally accepted that Hsp90 mainly interacts with proteins that are already folded to a large degree, the extent of folding of different client classes is not well dened.
19b The presence of tertiary or quarternary structural elements in the client, even if it is non-native, favours the search for common binding motifs, but this process requires co-chaperones or cofactors. In the case of repeated unsuccessful folding or aggregation, the E3 ubiquitin ligase CHIP, that is recruited to Hsp90, can initiate degradation via the proteasome pathway. The whole scenario has become more complex by a recent nding that Hsp90 interacts with the p53 client, in that p53 is actually unfolded by Hsp90a, as judged by NMR spectroscopic measurements. 55 As a consequence p53 adopts a molten globule-like state. Thus, Hsp90 should not be solely regarded as a chaperone that simply helps transform its clients into a stable and xed tertiary structure. Instead, Hsp90 also stabilises the dynamic molten globule state, which may foster other protein interactions for those clients.
Biomedical aspects of Hsp90

Selection criteria for Hsp90 as a target in chemotherapy
Hsp90 plays a key role in a diverse range of diseases, such as ischemia, reperfusion, infections and neurodegenerative diseases.
56 However, from a pharmaceutical point of view its participation in the development and control of various cancers is most important. In cancer cells, an increased Hsp90 expression parallels the overexpression of oncoproteins like Erb2, EGFR, c-RAF, HIF-1 and telomerase. These facts make Hsp90 a key target in cancer chemotherapy.
57 Signal transduction pathways like G-protein-coupled receptors, low-molecular-weight GTP binding protein, tyrosine kinase, Ser/Thr kinase, ion channel receptors, nuclear pore channel and nuclear transcription factors are important elements in several diseases and may also expand the opportunities for Hsp90-based therapies. By identifying cancer-specic interactomes, such as the Hsp90 inhibitor PU-H71 (12), Hsp90-dependent oncogenic client proteins have been captured by pull down assays. 58 This assay helped to comb through the cancer-linked proteome using mass spectrometry and new aberrant signalosomes in CML cells (Chronic Myelogenous Leukemia; cancer cell lines of white blood cells) were found. One important key regulator that was identied by this method is STAT5. STAT5 is a molecular regulator for proliferation, differentiation and apoptosis in hematopoietic cells, which are multipotent stem cells giving rise to all new types of blood cells.
Among the relevant oncoproteins, the transcription factor p53 is probably the most prominent one, sometimes being referred to as "guardian of the genome". In about 50% of all cancers, p53 is damaged and the loss of function is caused by so-called "hot spot" mutations in the DNA-binding region. 59 Functionally, the detection of DNA damage and subsequent initiation of apoptosis or repair mechanisms are the most important features of p53. A rescue mechanism of a defective p53 system is fatal, because the mechanisms of apoptosis can thus be evaded. Physiologically, tumor cells are under constant stress; so proteins actually tend to denature. 60 This situation leads to an increased consumption of molecular chaperones, as reected in an increase of the cytosolic Hsp90 fraction to up to 4-5%, which leads to higher heat shock protein activity in tumor cells compared to healthy cells. 61, 62 The effect of Hsp90 blockers is more pronounced in tumor cells than in healthy cells due to the higher concentration of Hsp90, which is accompanied by overproduction of Hsp90-dependent oncoproteins. The increased presence of the "multi-chaperone" machinery in cancer cells results in a higher affinity for inhibitors that bind to the N-terminus of Hsp90. In normal cells, the major amount of Hsp90 is not present in multi-chaperone complexes and in this state it shows lower affinity for inhibitors. As a result, inhibition initiates apoptosis or stops elevated growth rates.
In essence, the pronounced accumulation of Hsp90 in cancer cells along with the opportunity to develop selective inhibitors against Hsp90 and cancer relevant multi-chaperone complexes are important selection criteria to identify Hsp90 as a promising target in anticancer therapy.
Functional domains of Hsp90 -the Achilles heel
The establishment of Hsp90 as a biological target in anti-tumor therapy initiated the search for inhibitors in academia and the pharmaceutical industry. The most prominent Hsp90 inhibitor is geldanamycin (1) , that was rst isolated from the actinomycete Streptomyces hygroscopicus. Geldanamycin acts by binding to the N-terminal ATP-binding site of Hsp90, the ATPase function (see Fig. 6 ). 63 The affinity of geldanamycin for the ATPbinding site is 100-fold higher than that of ATP (Fig. 8) .
It binds to the site in that it adopts the structure of an unfolded polypeptide chain. The most important contacts of ATP interaction sites on the Hsp90N crystal are Met84, Asp79, Gly118, 121, 123, Phe124 and Thr170, while Asp79, Lys44, Lys98 and Phe124 are relevant for geldanamycin binding and the semisynthetic derivative 17AAG 12 (vide supra). They are not only relevant for the inhibitory role of geldanamycin but also for the semisynthetic derivative 17AAG 15 (vide supra). Upon binding of geldanamycin and analogues, Hsp90 is retained in its ADP-bound conformation so that these ligands prevent Hsp90 from promoting the ATP cycle (Fig. 5 and 6 ). As a result, the client protein is ubiquitinated and then degraded by the proteasomic machinery. Moreover, the inactivation and destabilisation of the hypoxia-induced factor (HIF)-1a is induced. This results in the degradation of HIF-1a. As a consequence of inhibition, apoptosis or programmed cell death is initiated. Another competitive ATPase binder is the polyketide radicicol (13). It was isolated as a secondary metabolite from the fungi Monocillium nordinii and Monosporium bonorden. Only recently, sulforaphane (14), an isothiocyanate derived from cruciferous vegetables, has been shown to possess potent chemopreventive activity by inhibiting pancreatic cancer cell growth (IC 50 $ 10-15 mM). It has been suggested that it also disrupts proteinprotein interactions in Hsp90 complexes. 64 
Hsp90 and drug design 68
The interest in Hsp90 inhibitors has recently found an additional impetus, because heat shock proteins can also serve as a target in the treatment of pathogenic diseases, such as malaria and leishmania, as well as against neurological disorders.
69
Although geldanamycin is a feasible drug candidate for targeting Hsp90, the search for improved drug candidates is still intensely pursued, particularly in order to reduce toxic side effects. Geldanamycin exerts a high degree of hepatotoxicity, which is thought to result from detoxication processes e.g. when a quinonimine is formed or thiols (such as glutathione) add to the quinone moiety by means of a Michael reaction.
70
Besides pharmacokinetic aspects, resistance, including polymorphism of the N-terminal binding site may render potential drugs like geldanamycin ineffective.
Mutational analysis of Hsp90 disclosed that the middle domain, particularly Trp300 and Glu341, have a predominant role in recognising client proteins in the closed dimeric structure.
71 Trp300 is part of an amphipathic loop structure that exerts hydrophobicity towards the core and hydrophilicity towards the solvent. This bifunctional arrangement may work like a 'hook' that captures the client via hydrophilic interactions. Since some clients may present a hydrophobic patch for interaction, the inner hydrophobic site in Hsp90 could mediate the process by insertion of the patch into this hydrophobic space.
72 These preliminary studies demonstrate that it would be highly desirable to identify a 'minimum client binding site', shared by the bulk of each client class. In fact, this would reduce the possible multiple interaction sites to one common point of contact, amenable to inhibitor development. Based on the X-ray analysis of the ATP binding pocket, other drug classes, including purine scaffold derivatives and tetrahydrobenzopyrimidines, have been evaluated.
73
A recurring problem common to all inhibitors that target the N-terminal ATPase site is the subsequent induction of Hsp70 and Hsp27 via Hsf1 (not shown). The proliferative effect of Hsp70/27 clearly counteracts the desired apoptotic effect to some extent. The degree of this effect, however, depends on the specic tumor. One strategy to circumvent this problem is to focus on other binding sites for inhibitors. Indeed, the Cterminus is a feasible alternative although the underlying mechanism is much less clear. The inhibition of Hsp90 imposed by eliminating the TPR2-mediated Hop/Hsp90 interaction has been demonstrated.
74
Novobiocin (9) 75,76 and cisplatin are both known to bind to this Hsp domain. Since a second ATP-binding site close to the C-terminus is hypothesised, it cannot be excluded that inhibition may be linked to this site instead. 77 However, binding to this site is oen weak and a more precise understanding of this area of Hsp90 will be mandatory for utilising it as a site for drug development. Notably, the direct inhibition of the client binding site is unknown and has not been studied in great detail so far.
Synthetic approaches towards natural product based libraries of Hsp90 inhibitors
General considerations
In view of its central position in a myriad of cell processes and its special role in the life cycle of cancer cells there is a quest for the development of highly potent inhibitors targeting Hsp90.
Geldanamycin (1) (Fig. 9) . The following discussion will provide a detailed description on strategies of how to generate derivatives of this lead compound that are structurally as complex as geldanamycin. This showcase demonstrates the synthetic difficulties and restrictions associated with creating related natural product libraries.
Total-and semisyntheses are most widespread approaches in natural product chemistry.
78 A third synthetic tactic relies on implementing biological tools into synthetic strategies. These may be enzyme cocktails from secondary metabolisms or organisms engineered in the biosynthesis of the target natural product. Powerful methods are combinatorial biosynthesis 79 or mutasynthesis.
80-82 These are combinations of partial biosynthesis and semisynthesis 83 or precursor directed methods.
84
Besides their biological potency, ansamycin antibiotics, such as geldanamycin, are also unique from a synthetic point of view, because all three synthetic tactics have been successfully pursued, as summarised in Fig. 10 . Details on how modica-tions were achieved are given in the following chapters.
Total synthesis approaches to geldanamycin and derivatives
The total synthesis of geldanamycin (1) and related ansamycin natural products is still a formidable multi-step challenge. Herbimycin A (2) was the rst natural product of this class of ansamycin antibiotics to be synthesised by Nakata et al. in 1991. 85 A decade later, Andrus and co-workers achieved the rst total synthesis of geldanamycin (1) . This work has become a benchmark synthesis, because it unravelled some very challenging hurdles. Thus, the best timing for incorporating the aromatic/quinone moiety into the backbone has to be considered and along with this it is crucial to choose the best protecting group strategy for the functional groups on the aromatic ring. Thus, the methoxy group at C-17 is prone to undergo side reactions when selective demethylation at C-18 and C-21 of advanced synthetic intermediate 17 was pursued (Scheme 1). Instead of formation of the quinone form of geldanamycin formation, the oxidative deprotection preferentially yielded ortho-quinone derivative 18 (Scheme 1). The low yielding synthesis of geldanamycin (1) could later be improved by Andrus and co-workers by switching to MOM protection of the hydroquinone moiety.
86
Panek and co-workers disclosed an alternative total synthesis, which provided geldanamycin (1) in 20 linear steps in 2% overall yield (Scheme 2). 87 A key to success was the choice of isopropylethers as protection for the hydroquinone moiety. Attachment of the ketide chain to the aromatic ring 19 was achieved by a [4 + 2] ring closure with allyl silane A to yield two diastereomers 20a and 20b 88 followed by a stereoselective hydroboration that furnished compound 21. This remarkable pyran formation is suggested to proceed via a cyclic transition state, which is formed aer removal of the a-siloxy group in A. Subsequent reductive ring opening of the pyran ring using Sc(OTf) 3 /Et 3 SiH yielded key fragment 22.
The macrolactamisation to 24 was accomplished by an intramolecular copper-mediated Hartwig-Buchwald type reaction between the aryl bromide moiety and the amide functionality in 23. The benzyl ether and both isopropyl groups were removed by using AlCl 3 in the presence of anisole to furnish dihydrogeldanamycin that was subsequently treated with Pd/C under oxidative conditions to give geldanamycin (1) in 55% yield over two steps.
Furthermore, Panek's group utilised this synthetic approach for the preparation of autolytimycin (4), reblastatin (5), and three analogues 28-30. Predictably, the end game for these phenolic ansamycin derivatives turned out to be easier to Scheme 1 Ortho-quinone 18 formation by oxidative demethylation of geldanamycin derivative 17. perform than for the hydroquinonoic geldanamycin described above (Scheme 3).
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Bach's work 90 (Scheme 4) demonstrates that future work on the end game synthesis of quinone-based macrolactam antibiotics will have to address an alternative protection strategy for the hydroquinone moiety. Bach et al. based their sequence on connecting C8 and C9 via a SmI 2 -mediated Reformatsky coupling reaction of a-chloro ketone 32 with aldehyde 33 to yield advanced intermediate 34. This product was transformed by Martin elimination into enone 35. 90 However, aer lactam formation all efforts failed so far to remove the isopropyl groups so that the total synthesis had to be terminated at the stage of the bisisopropyl geldanamycin derivative 36 (Scheme 4). Clearly, geldanamycin (1) remains a true synthetic challenge and future SAR studies cannot be expected to rely on total syntheses approaches alone.
Andrus et al. simplied the total synthesis approach to new geldanamycin derivatives by installing an amide bond into the ansa chain. By merging two different fragments 37 and 38 with the advanced ansa chain fragment 39 they nally accessed geldanamycin 8,9-amido-geldanamycin derivatives 40a and 40b, respectively (Scheme 5). Unfortunately, both new geldanamycin derivatives have lost their ability to promote HER2 degradation in SK-Br3 cells (ED 50 > 20 mM, compared to geldanamycin with an ED 50 of 5 nM). Most known geldanamycin derivatives were prepared by semisynthesis and in the majority of cases they are modied at C-17. Rinehart et al. synthesised geldanamycin derivatives, named geldanazines and geldanoxazinones by reacting geldanamycin with o-phenylenediamines and o-aminophenols, respectively, via imine-formation at C-18 and substitution of the C-17-methoxy-group by means of an addition/elimination process (Scheme 6). Both groups of derivatives showed low inhibitory effects on the bacterial RNA polymerase but they exerted higher potency in inhibiting the DNA polymerase of tumor cells compared to geldanamycin (1), while showing reduced cytotoxicity. Remarkably, all new geldanamycin derivatives except 44a, 43e and peptide 43g inhibited a new biological target, namely the RNA-dependent DNA polymerases (RDDP) of the Rauscher Leukemia Virus (RLV), which geldanamycin does not address.
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Other "early" semisynthetic modications of geldanamycin included hydrazone and oxime-formation at C-19 as depicted in 46 (Scheme 7). These were obtained by Mannich condensation of geldanamycin (1), followed by the reaction of the proposed intermediate alkylimines 45a with amines or hydroxylamines, respectively. These derivatives showed good activity against tumor viruses while exhibiting lower Scheme 4 Total synthesis of 18,21-diisopropyl-geldanamycin hydroquinone 36 (according to Bach et al. 90 ).
Scheme 5 A simplified total synthesis of geldanamycin derivatives 40a and 40b. cytotoxicity compared to geldanamycin (1) (Scheme 7). The hydrazones 46b and 46c showed 3000-25 000 times lower antiproliferative activity towards BALB 3T3 cells than geldanamycin, while the oxime 46j was only 200-500 times less cytotoxic. 93 When repeating this experimental work, Schnur and cowokers 94 also prepared compound 46a and beyond this they assigned the originally proposed intermediate 45a to be the cyclic isomer 45b.
In 1995 Schnur et al. reported several semisynthetically generated geldanamycin derivatives that were modied at C-17 and at C-19, respectively.
95 Geldanamycin (1) and 4,5-dihydrogeldanamycin 47 were reacted with alkylamines to yield 17-demethoxy-alkylamino-derivatives 48 and 49 (Scheme 8). In case of sterically hindered amines, the C-17 position was the preferential site of attack; instead the C-19 alkylamino-or the C-17, C-19 bisalkylamino compounds were obtained. This modication allowed to rapidly generate a structurally diverse library of simple geldanamycin analogues from which two the derivatives 17-N-allylamino-17-demethoxygeldanamycin (17AAG; tanespimycin) 15 and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG; alvespimycin) 16 (Scheme 12) were further elaborated as drug candidates.
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These rst semisynthetic studies revealed improved biological potency/activity when small, sterically unconstrained aminogroups are introduced at C-17 (e.g. 48a, 15, 48c, 48g-h, 48k-l showed highest activities. Small amino-substituents at C-17 carrying acidic functions are less potent (see 48p, 48r). In contrast, basic groups and hydroxyl groups are tolerated. When substituents become bulkier or arylalkylamines are introduced the activity is reduced. Later, Le Brazidec added amides, carbamates and ureas as well as 17-aryl derivatives to the portfolio of 17-N-geldanamycinderivatives by making 17-amino-17-demethoxygeldanamycin (17-AG) 48a accessible. This derivative was generated by treatment of geldanamycin with methanolic ammonia and was further transformed into amides, ureas and carbamates (Schemes 9-11). The aromatic amides 50a-c and 50g-h are more potent than the aliphatic analogues 50k. Structural changes with respect to size and polarity resulted in reduced activity (50i, 50j). Increasing the electron density in the aromatic system turned out to be particularly effective for ortho and meta substituents.
50d and 50e (both IC 50 ¼ 180 nM) showed higher activity in the Her-2 degradation assay in intact MCF7 cells compared to 50f (IC 50 ¼ 400 nM). Electron withdrawing groups in the para position had no effect on biological activity (50g, 50h).
Treatment of p-chloromethylphenyl geldanamycin derivative 50b with secondary amines gave access to amides 51a-j (Scheme 10). In the series of tertiary amine-derivatives, benzylalkylamines, such as 51c, were three times more active than dialkylamines, such as 51b. Comparison of the cyclic amines revealed that 4-arylpiperazines 51d-f showed superior potency over piperidine derivative 51g.
Urea 52a as well as carbamates 52b-e were synthesised in an analogous fashion starting from 17-AG 48a (Scheme 11). The corresponding 17-aryl substituted geldanamycins 53a and 53b were prepared by a Suzuki cross coupling reaction under Neel's conditions using the corresponding triates as activated geldanamycin derivatives.
Biological tests revealed that carbamate 52d (cell line Her-2: IC 50 ¼ 50 nM) is the most active one within this carbamate series, while urea derivative 52a showed no antiproliferative activity.
A very large compound library covering more than sixty 17-alkylamino-17-demethoxy geldanamycin derivatives was reported by Tian et al. in 2004 (Fig. 11 and 12) . It was the goal to nd potent and water soluble HSP90-inhibitors. At least twenty derivatives showed cell growth inhibition potencies similar to 17-allylamino-17-demethoxygeldanamycin, 17-AAG, 15. 98 In terms of water solubility one of the most promising compounds was 17-(2-dimethylaminoethyl)-amino-17-demethoxygeldanamycin (17-DMAG, 16), which was independently prepared by the NCI. In this broad SAR-screening several classes of side chains for the C-17-amino-group were investigated: a) a series of homologues to elucidate the effect of side chain size on activities 54a-l, b) a series of hydrophilic derivatives to enhance water solubility 55a-h, c) a series of derivatives bearing rigid elements of branching in the side chain for improving binding affinity 16 and 56a-g, d) a series of derivatives bearing substituted ethylenediamines 57a-p and e) a series of derivatives that comprise cyclic amines at C-17 58a-f.
A two carbon linker unit appears to provide the optimal side chain length for highest antiproliferative properties towards Scheme 9 Semisynthesis of C-17-derivatives 50a-k.
Scheme 10 Semisynthesis of C-17 modified derivatives 51a-j.
Scheme 11 Semisynthesis of C-17-modified geldanamycin derivatives 52a-e and 53a,b.
Scheme 12 Preparation of hydrochloride salts (hydroquinone form) 60a*,b* and 61*.
SK-Br3 cells; bulkier groups lead to reduced activities. The most signicant effect is registered if the branching is located close to the amine. Substitution at the a-position as in 54i (IC 50 ¼ 130 nM) furnished a marked decrease of activity compared to b-substitution as in 57j (IC 50 ¼ 50 nM). Carboxylate 48p (see Scheme 8) was inactive and heterocyclic analogues 56d-e showed modest potency. Among the diamines, a two-carbon spacer provides the optimal side chain length, too. Thus, the potency of derivative 16a (n ¼ 2; IC 50 ¼ 24 nM) is more than 10-fold higher than 56a (n ¼ 4; IC 50 ¼ 350 nM) while binding affinities of these compounds in Hsp90-assays are similar.
Exchange of the dimethylamino group in 17-DMAG 16 by cyclic amines gave mixed results. The aziridinyl analogue 57e (IC 50 ¼ 16 nM) showed the highest level of cytotoxicity, followed by the azetidinyl analogue 57f (IC 50 ¼ 26 nM). The cytotoxicity decreases with larger ringsizes. The terminal nitrogen atom in 57a can be transformed into the corresponding N-oxide 57k or converted to a quaternary ammonium salt 57l resulting in geldanamycin derivatives forfeiting cytotoxic activities while maintaining the Hsp90 binding activities. Notably, more than twenty of the derivatives screened had IC 50 values below 100 nM. At least ten of these compounds are more soluble in phosphate buffer (pH 7) than 17-AAG 15. Small linear side chains lead to an increase in cytotoxicity compared to branched chains. Another important outcome of this study is that in vitro binding to puried Hsp90 cannot generally be related to cytotoxicity. This may be rationalised if one assumes differences in drug concentrations under in vitro and in vivo conditions.
In the year 2006 Porter et al. studied highly soluble hydroquinone-hydrochloride derivatives that are related to 17-AAG 15 and some of their physiological metabolites. 17-AAG 15 was reduced to the corresponding hydroquinone by sodium hydrosulte, which was precipitated to provide ammonium salt 60c* in high purity (Scheme 12). 99 In vivo, 17-AAG 15 is readily metabolised to diol 59 and to the dealkylated analogue 17-AG 48a. These compounds were also transformed into the hydroquinone hydrochloride derivatives 60a* and 61*, respectively, that showed similar solubility and stability proles as hydroquinone 60c*.
It was shown in cellular assays that the hydroquinone moiety is present in a redox equilibrium with the quinone. In order to prevent oxidation of hydroquinone derivative 60c* under the conditions of the biochemical and cellular assays, Porter et al. 99 locked the hydroquinone 60c* in form of the cyclic carbamate 62 and the amide 63, respectively (Scheme 13).
Hydroquinone 60c* (EC 50 ¼ 63 nM) appears to exhibit a twofold higher affinity for human Hsp90 compared to the quinone 15 (EC 50 ¼ 119 nM), whereas derivatives 48a and 60a* (both EC 50 ¼ 34 nM) essentially exerted the same affinity for Hsp90. The "locked" hydroquinones 62 and 63 do bind to Hsp90 but more weakly than their acyclic counterpart 60c*.
Indeed, Schnur et al. demonstrated that the quinone form of geldanamycin (1) can be cleanly converted into its hydroquinone form 1* using sodium dithionite, a process which is slowly reverted under air. However, the hydroquinone form can be stabilised aer acylation and provided stable triacetate 64 (Scheme 14).
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Blagg et al. attached biotin to geldanamycin via photolabile and nonphotolabile tethers, respectively (Scheme 14). The tethers incorporated both hydrophobic and hydrophilic groups. 17-Amino-derivatives 65 were prepared in the usual manner and the terminal amino group was then coupled with the biotin functionalised linker 66a or alternatively with the more hydrophilic PEG-derivatives 66b or 66c to yield conjugates 67 and 68, respectively (Scheme 15). 100 Biotinylated geldanamycin conjugates 69 and 70 containing photolabile linkers were also prepared in a similar fashion (Fig. 13) .
These conjugates served as biochemical tools for the development of Hsp90 assays. Incubation of 67a with puried recombinant Hsp90 from yeast followed by affinity purication using a resin functionalised with neutravidin resulted in the capture and release of Hsp90. Incubation of 67a with Jurkat A3 proteome yielded several proteins, including Hsp90. The main goal of this assay was to search for other possible proteins binding geldanamycin and thus verifying whether geldanamycin is what is called a "dirty" drug, that targets more than one biological receptor or pathway.
In 2012 Wuest and co-workers published uorine-and rhenium-containing geldanamycin derivatives as precursors for the corresponding 18 F-labeled and 99m Tc-labeled molecular probes useful for imaging in vivo Hsp90 expression (Fig. 14) .
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Fluorobenzoylated derivative 72a exhibited highest Hsp90 ATPase inhibitory potency comparable to geldanamycin (1). In the ATPase assay, the uorobenzyl-functionalised geldanamycin derivative 71b and the tricarbonyl-rhenium complex 73 were the least active compounds while compounds 48k, 71a and 72b reduced ATPase activity by 50-65%.
Sun et al. developed a prodrug concept for geldanamycin by preparing a galactose-geldanamycin glycoconjugate 74 (Fig. 15) . The carbohydrate moiety is linked via C-17 and is supposed to undergo in vivo activation by b-galactosidases thereby liberating geldanamycin derivative 75, which ought to bind to Hsp90 in a similar manner as 17-aminogeldanamycin 48a does.
102
Using a similar concept, Wang et al. prepared a series of geldanamycin glycoconjugates 76a-e based on galactose, glucose and lactose to be used as prodrugs for enzyme activation (Fig. 16) . 103 Glycoconjugate 76a (cell line SW620: IC 50 ¼ 70 nM and HT29 IC 50 ¼ 104.7 nM) showed antiproliferative activity, while galactose-and lactose-derived conjugates 76b-e were all inactive. A b-glucosidase was proposed to be responsible for the unexpected cleavage of glucose in 73a, which would explain its strong antiproliferative activity.
Finally, the quinone unit can also be transformed into the 7,6-ring iminoquinone 77 as well as 5,6-fused ring systems 78 (Scheme 16). Reduction of 78a and 78g to their hydroquinones afforded unstable products that quickly yielded the quinones in the presence of air.
Most geldanamycin derivatives that are cyclised at C-17, C-18 are active; in cases of 78a (IC 50 ¼ 50 nM), the antiproliferative activity is similar to geldanamycin (1). Even the ring enlarged Starting from semisynthetically modied geldanamycin 48g (see Scheme 9), removal of the carbamoyl group yielded 79 and from here the resulting 7(S)-amino derivatives 84a and 84b were generated with double stereocontrol and overall retention of conguration at C-7.
An important transformation is the selective bromination at C-19 to yield bromide 85, which can be utilised in a similar manner as described for the preparation of the geldanamycin derivatives 86. Here, the addition-elimination mechanism is favoured for the bromide because of its better nucleofugic properties compared to the methoxy group at C-17. With selected amines geldanamycin derivatives 86a and 86b were obtained (Scheme 18). When incorporating substituents at C-19 a strong reduction of antiproliferative activity takes place (see 86a,b).
Schnur et al. also pursued semisynthetic changes on the straightforwardly accessible functional groups of the ansa-ring. Geldanamycin and 4,5-dihydro derivative 48 and 46 served as a starting point for further changing the macrolactam nitrogen atom as well as the hydroxyl group at C-11 (Schemes 19-23). Thus, N-substituted derivatives 87a-k and 88, 11-O-acyl products 89a-g, 7-deamidinated analogues 90a,b, esters 91a-c, 7-keto-analogue 92, 11-keto-derivatives 93a-b and 93d, 11-oximes 94a-b, 11-amino derivatives 95a-b and 11-(S)-uoro derivatives 96a-d were accessed by Schnur et al.
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These studies demonstrated that 17-azetidine and 17-allylamino-derivatives are among the most potent C-17 analogues. Still, the lowest IC 50 were determined for the free amino derivatives such as aminogeldanamycine derivatives 87f (IC 50 ¼ 230 nM) compared to 87k, (IC 50 ¼ 1900 nM). N-Pyridylmethyl derivative 87j was >100 fold less potent than analogues bearing a carbonyl group in the a-position of the N-alkyl group (e.g. 87a or 87i, respectively). Phenacyl-analogues 87b (IC 50 ¼ 80 nM) and 87j (IC 50 ¼ 70 nM) show similar antiproliferative activity to geldanamycin (1) (IC 50 ¼ 70 nM).
Acylation of the hydroxyl group at C-11 (Scheme 20) could also be achieved and provided new derivatives 89a-g with similar biological activities compared to their unsubstituted precursors. Removal of the amidinoyl group gave geldanamycin derivatives 79 and 90a,b; both have lost their biological activity. The same change of biological properties occurred, when the amidinoyl group was exchanged by other acyl groups at C7 as in geldanamycin derivatives 91a-c or aer oxidation of C-7, as in 92 (Scheme 21). Clearly, the free carbamoyl group acts as a pharmacophore. It is suggested that Asp40 and Lys44 in the ATP-binding domain of Hsp90 are essential for binding of the quinone moiety of geldanamycin.
Specic exchange of selected amino acids in the highly conserved ATP-binding site (Lys44 by arginine and Lys89 by aspartate) suggest they stabilise the quinone ring. Other important positions that have an effect on geldanamycin binding are Glu88 (demonstrated by exchange with glycine) and Asp92 (demonstrated by exchange by leucine). 104c,d Double exchange mutations (Lys44 by arginine and Lys89 by asparagine) in the yeast chaperon homologue Hsp82 did result in decreased sensitivity towards 17-AAG 12, perhaps due to weakened binding to the C-12 methoxy group on (1).
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Oxidation of the hydroxyl group at C-11 yielded ketones 93a (IC 50 ¼ 220 nM) and 93b (IC 50 ¼ 34 nM) and 93c (IC 50 ¼ 34 nM), all of which showed superior potency to the oximes 94a/IC 50 ¼ 270 nM) and 94b (IC 50 ¼ 1100 nM). Reductive amination afforded amino derivatives 95a and 95b, respectively, which were less active than both the corresponding alcohols and the ketones.
An interesting semisynthetic transformation allows the introduction of a uoro substituent at C-11 with inversion of conguration using diethylaminosulfur triuoride (DAST). In vivo studies revealed that two of the four new uorinated derivatives, namely 96a (IC 50 ¼ 46 nM) and 96b (IC 50 ¼ 50 nM) showed very good antiproliferative activity. These in vivo studies are noteworthy, because many new geldanamycin derivatives obtained by semisynthesis showed hardly any in vivo activity, such as 87h,i, 89b,f,g and 93a,d, despite being active in vitro.
Rastelli et al. also prepared geldanamycin derivatives that varied at C-7 (Scheme 24). The carbamoyl group is integrated in a hydrogen bonding network that involves four water molecules. By modifying the substituent at C-7 insight into the importance of this network was gained. Saponication of the carbamoyl moiety followed by reaction with carbodiimidazole (CDI) and trapping of the CDI-adduct with nucleophiles (hydrazine, hydroxylamine) furnished new 7-N-alkyl-carbamates 98a-o. 105 The majority of these derivatives showed no biological activity and only low Hsp90 affinity. Only 98f-k and 98m were active towards SK-Br3 cells in the range of around 0.5 mM.
Geldanamycin derivatives by manipulation of its biosynthesis
Over the past decade, the combination of metabolic engineering of biosynthetic pathways that code for secondary metabolism with semisynthetic modications has emerged as a powerful tool for the creation of derivatives of structurally complex natural products that are difficult to access otherwise. The preciseness of the biosynthetic machinery that is able to construct complex frameworks and macrocycles in a rather linear fashion meets chemical synthesis with its enormous exibility for introducing functional groups, including pharmacophoric ones that are unprecedented in nature.
5.4.1 Exchange of individual enzymes by genetic engineering. Due to its pharmaceutical importance the biosynthesis of the heat shock protein inhibitor geldanamycin was studied in detail, 106 allowing initiation of different metabolic engineering programs with the aim to generate geldanamycin derivatives.
Kosan Biosciences, Inc disclosed an elegant strategy that relied on the genetic manipulation of the geldanamycin polyketide synthase (GdmPKS) Streptomyces hygroscopicus 107 that provided several new derivatives lacking methyl or methoxy groups in the ansa chain. 108 The strategy is based on the substitution of acyltransferase (AT) domains in six different GdmPKS modules that commonly accept methylmalonyl-CoA or methoxymalonyl-CoA, by malonyl AT domains from the rapamycin PKS. 109 Overall this engineering of the biosynthesis provided 2-desmethyl, 6-desmethoxy, 8 (Fig. 16) . The authors speculated that enhanced structural exibility allows more facile preorganisation in the Hsp90-bound conformation in solution.
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Hong and coworkers followed a similar approach. Site directed mutagenesis of the geldanamycin polyketide synthase (PKS) and selected post-PKS tailoring genes provided several C-15 hydroxylated non-quinone geldanamycin analogues. One new derivative, 15-hydroxy-17-demethoxy analogue 107, exhibited stronger inhibition of Hsp90 ATPase activity by a factor of almost ve than geldanamycin. 112 A mutant strain from Streptomyces hygroscopicus subsp. duamyceticus (JCM4427), which lacked the active carbamoyltransferase, provided geldanamycin derivative 108 as the main fermentation product. Obviously, genetic interference also blocked the last biosynthetic step leading to the desaturation at C-4,C-5. The missing carbamoyl group renders this metabolite biologically inactive (see above). Next, this 4,5-dihydro geldanamycin derivative 108 was treated with trichloroacetyl isocyanate to yield bis-carbamoyl derivative 110. This compound was treated with various amines to introduce an amino substituent at C-17 (see also Scheme 8) to provide 4,5-dihydro derivatives 112a-d. For comparison purposes also the 17-aminated 7,11-bis-carbamoylderivatives 111a,c-e were chemically prepared from geldanamycin (1) via 109 (Scheme 26).
As expected compound 108 is inactive as opposed to carbamoylated 4,5-dihydrogeldanamycin 47. The C-7,11-bis-carbamates 112a-d carrying an aminoalkyl substituent at C-17 exert a broad scope of antiproliferative activities. 112c (cell line SK-Br3: IC 50 observations from semisynthetic studies towards similar derivatives like 91.
Several groups employed mutant strains of S. hygroscopicus that are specically blocked in the biosynthesis of the PKS starter building block 3-amino-5-hydroxybenzoic acid (see Scheme 25) 50 : 17-120 nM) turned out to be as active as geldanamycin. In contrast, aza-geldanamycin 127 was inactive in assays determining antiproliferative activity.
Mutasynthon 128 provided a remarkable number of differently processed geldanamycin derivatives being fed to the AHBA blocked mutant of S. hygroscopicus. Besides the expected products 129 and 130, the blocked mutant strain also provided 20-membered macrolactones 133a-c. Obviously, the benzyl alcohol competes as a nucleophilic function with the anilino group for the PKS-bound seco acid during amide synthase-promoted macrocyclisation. These results were further generalised by feeding benzoic acids 131 and 132 containing an additional benzyl alcohol which resulted in the formation of macrolactones 134 and 135, respectively (Scheme 28).
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Geldanamycin derivatives 129b and 129c and 130b showed good (130b IC 50 ¼ 22-470 nM) to moderate antiproliferative activities towards different cancer cell lines while 129a and 130a were >100 fold less potent than geldanamycin (1). The 20-membered lactones 133a-c, 134 and 135 exhibited no antiproliferative properties or Hsp90 binding affinity at all.
Assaying inhibitory effects on Hsp90 function by high throughput screening
The rising demand for compound libraries has led to the development of fully automated high-throughput screening devices (HTS). Test protocols in pharmaceutical industry are commonly target-oriented, i.e. the interaction of a test compound with a biological target is investigated. The HTS results are analysed in a statistical manner and a positive assay response is called a "hit". Clearly, the quality of HTS-derived results are associated with too many false positive responses from which the few true leads have to be found by laborious deconvolution. In addition, no statement on pharmacokinetics of the "hit", such as toxicity, membrane permeability and solubility of the identied substance, is possible at this stage. The typical HTS setup utilises the microplate format for assaying and trailing target-inhibitor complexes. It commonly relies on a biochemical reaction in which a substrate is functionalised with a radioactive or uo-rescent label. For identifying potential inhibitors for Hsp90, various methods are known for how HTS can be performed. These are a) cell-based assays, b) refolding assays and c) binding assays. The classical cell-based assay addresses antiproliferation and combines activity and selectivity. 117 The folding assay addresses the function of Hsp90 as a molecular chaperone (Fig. 17A) . Here, the enzyme luciferase is employed. It catalyses the oxidation of luciferin to unstable oxyluciferin and its decay is monitored as a chemiluminescence signal. 118 In this assay the capability of Hsp90 to refold heat denatured luciferase to an active luciferase form is exploited. In the presence of Hsp90 inhibitors inhibition of chaperone function is observed, leaving luciferase denatured. The loss of chaperone function correlates with the decrease of chemiluminescence.
Another type of assay, the specic binding of a potential inhibitor and Hsp90, is being investigated. In this context various methods have been developed. These include the ATPase activity assay (Fig. 17B) , the proteolytic ngerprint assay combined with mass spectrometry, the thermal shi assay, fragment screening using affinity capillary electrophoresis (CEfrag), surface plasmon resonance (SPR), thermophoresis, the uorescence polarisation technique and TIRF (total internal reection uorescence). This latter technique is well-suited for analysis of biomolecular interactions and mechanistic studies of biomolecular events. Finally, the Alpha (Amplied Luminescent Proximity Homogeneous Assay) Screen is a very sensitive non-radioactive homogeneous, but expensive assay technology that allows the screening of interaction on a high accuracy level using donor and acceptor beads.
13b,15,58,119,120 Formats suitable for a colorimetric quantication are also frequently used; in the case of Hsp90 this is achieved by detecting inorganic phosphate as a phosphomolybdate complex.
121a Fluorescence polarisation utilises a geldanamycin derivative as Hsp90 inhibitor that is labeled with uorescein isothiocyanate (FITC) (Fig. 17C) .
Microscale thermophoresis (MST) is a novel technique that allows the characterisation of biomolecules in a label-free fashion. The method is able to detect changes in thermophoretic mobility induced by ligand binding. Several factors such as size, charge and solvation entropy inuence the mobility of the biomacromolecule and it has been shown that this is a highly sensitive technique to distinguish between binding and nonbinding.
121b,c
The use of these assays as well as cell growth test provided a detailed overview on the structure-activity relationships (SAR) of geldanamycin (1) as a lead structure. The previous chapter not only gave a detailed summary of how libraries of analogues have been prepared but also provided information on antiproliferative activity for most derivatives. Indeed, more than 500 geldanamycin derivatives have been reported to be assayed up to date. A qualitative conclusion of these structure-activity relationship studies can be drawn and consequently a "SAR map" can be created that is depicted in Fig. 18 .
Outlook
Geldanamycin has emerged as a show case tool for unraveling a new mechanism of cell biology (Hsp90) and establishing it as a new biological target with therapeutic relevance. The penicillins (bacterial transpeptidase) and paclitaxel (Taxol Ò ) (polymerisation of tubulin) are other famous natural product examples that were starting points for target driven pharmaceutical research programs. In the case of Hsp90, the natural products novobiocin (9) and radicicol (13) accompanied this profound interest in cell biology and biochemistry of heat shock proteins. Geldanamycin (1) and radicicol (13) have become lead structures for cancer driven research on Hsp90. Several geldanamycin analogues are in clinical trials, such as 17-AAG 15, the corresponding hydrochloride salt 136 (Bristol-Myers Squibb) and amino geldanamycin 48a (Innity Pharmaceuticals) (Fig. 19) . Radicicol (13) is structurally simpler than geldanamycin and typical medicinal chemistry programs provided new derivatives 137 (Novartis), 138 (Kyowa Hakko Kirin Co., Ltd) and 139 (Synta Pharmaceuticals Corp.) with strong anticancer activities based on Hsp90 inhibition.
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So far, no Hsp90 inhibitor has reached commercialisation and it remains to be seen whether an Hsp90 inhibitor will ever be a drug. Future developments may have to investigate the contribution of Hsp90 paralogues to the observed activity of these established inhibitors. Indeed, rst results indicate that there could be applications of Hsp90 inhibitors beyond cancer. These studies indicate that Hsp90 and Hsp70 have roles in human immune response and Hsp90 may promote the stability of oligomeric Tau and b-amyloid peptides, thought to be toxic species involved in the pathology of Alzheimer's disease. Cancer selective responses in Hsp expression and their clients will therefore require a ne adjustment in combinatorial therapies (see also Fig. 2) . 117 A putative answer to the cancer expression barcode could be a combinatorial set of different ansamycin derivatives synthesised, as shown recently, and desirably tested on commercially available Hsp microarrays.
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Undoubtedly, this decade will answer the question of whether Hsp90 is a druggable target, especially in cancer therapy.
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